Publication Policy

Lilly has had a public policy on disclosure of clinical trial data since 2003 to disclose publicly all medical research results that are significant to patients, health care providers or payers—whether favorable or unfavorable to a Lilly product—in an accurate, objective, and balanced manner for customers to make more informed decisions about its products.

As part of the Principles for Responsible Clinical Trial Data Sharing, Lilly reaffirms our commitment to consider for publication all company-sponsored clinical trials in the scientific literature irrespective of whether the results of the sponsors’ clinical trials are positive or negative. At a minimum, results from all Phase 3 clinical trials and any clinical trial results of significant medical importance should be submitted for publication. This commitment also pertains to investigational medicines whose development programs have been discontinued.